文献速递肝病

自动化低流量腹水泵治疗难治性腹水的系统评价与荟萃分析

Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-03

该系统评价与荟萃分析纳入9项研究(8项病例系列和1项随机对照试验),评估自动化低流量腹水泵在肝硬化难治性腹水患者中的疗效与安全性。结果显示,泵植入后无需大量腹腔穿刺的合并估计率为0.62(95%CI 0.49-0.74),急性肾损伤发生率为0.30(95%CI 0.17-0.47),细菌性腹膜炎为0.27(95%CI 0.13-0.49),尿路感染为0.20(95%CI 0.09-0.37)。泵植入后血清肌酐平均升高23 µmol/L(95%CI 10-35),泵相关副作用合并估计率为0.77(95%CI 0.64-0.87)。

要点

  • 多数难治性腹水患者泵植入后无需大量腹腔穿刺。
  • 急性肾损伤发生率30%,肌酐平均升高23 µmol/L。
  • 细菌性腹膜炎和尿路感染发生率分别为27%和20%。

核心结论

  • 多数接受自动化低流量腹水泵治疗的患者泵植入后无需大量腹腔穿刺。
  • 急性肾损伤发生于30%的患者,泵植入后肌酐水平平均升高23 µmol/L。
  • 细菌性腹膜炎和尿路感染分别发生于27%和20%的患者。

研究设计与样本

  • 系统评价与荟萃分析,检索电子数据库评估自动化低流量腹水泵治疗难治性腹水的试验。
  • 共纳入9项研究,其中8项为病例系列,1项为随机对照试验。

主要发现

  • 泵植入后无需大量腹腔穿刺的合并估计率为0.62(95%CI 0.49-0.74)。
  • 急性肾损伤的合并估计率为0.30(95%CI 0.17-0.47)。
  • 细菌性腹膜炎的合并估计率为0.27(95%CI 0.13-0.49)。
  • 尿路感染的合并估计率为0.20(95%CI 0.09-0.37)。
  • 泵植入后血清肌酐平均升高23 µmol/L(95%CI 10-35),研究间无异质性。

临床怎么用

  • 对于肝硬化难治性腹水患者,自动化低流量腹水泵可减少大量腹腔穿刺需求。
  • 需监测急性肾损伤(发生率30%)及感染(细菌性腹膜炎27%、尿路感染20%)等并发症。

局限性

  • 纳入研究多为病例系列,仅1项随机对照试验。
  • 研究间存在高度异质性,排除平均或中位MELD评分>15的研究后异质性常降低或消失。
  • 敏感性分析结果与总体分析相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few effective treatments are available for patients with cirrhosis and refractory ascites. New treatment modalities are needed for these patients. AIM: To synthesise the available evidence on the efficacy and safety of automated low-flow ascites pump therapy in patients with cirrhosis and refractory ascites. METHODS: Electronic databases were searched for trials evaluating automated low-flow ascites pump therapy in patients with refractory ascites. RESULTS: Nine studies were included. Eight were case series, one was a randomised controlled trial. Pooled estimate rates were 0.62 (95% CI = 0.49-0.74) for the absence of requirement of large volume paracentesis (LVP) after pump insertion, 0.30 (95% CI = 0.17-0.47) for acute kidney injury, 0.27 (95% CI = 0.13-0.49) for bacterial peritonitis and 0.20 (95% CI = 0.09-0.37) for urinary tract infection. There was high heterogeneity between studies which was often reduced or eliminated in sensitivity analyses by excluding studies of patients with a mean or median model for end-stage liver disease (MELD) score > 15. Results of sensitivity analyses were similar to those of overall analyses. Mean increase in serum creatinine level after pump insertion was 23 µmol/L (95% CI = 10-35) with no heterogeneity between studies. The pooled estimate rate for pump-related side effects was 0.77 (95% CI = 0.64-0.87) with low heterogeneity between studies. CONCLUSION: This meta-analysis demonstrates that most patients treated with automated low-flow ascites pump therapy do not require LVP after pump insertion. Acute kidney injury occurs in 30% of patients and creatinine levels increase by a mean of 23 µmol/L after pump insertion. Bacterial peritonitis and urinary tract infection occur in 27% and 20% of patients respectively.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lepida A, Marot A, Trépo E, et al. Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites. Aliment Pharmacol Ther. 2019. PMID: 31583729. doi:10.1111/apt.15502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。